Understanding Prognostic Factors in Esophageal Cancer Patients
Official title: Noninvasive Testing Procedures, Role of Biomarkers and Anticancer Treatments in Esophageal and Esophagogastric Cancer Survival and Quality of Life of Patients With Cancer of the Esophageopharyngeal and Oesophageophageophageal Junction
Run by Semmelweis University · NCT06713993 · Data updated 2026-11-12
This study looks at patients with esophageal cancer to see which health factors might affect their recovery and overall well-being.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Semmelweis University Academic / other |
| Locations | 1 site (Budapest) |
| Status | Recruiting |
| Started | September 10, 2024 |
| Main results expected | September 30, 2029 |
| Study ends | September 10, 2034 |
| Registry record updated | April 24, 2026 |
| Trial ID | NCT06713993 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 years diagnosed with new-onset esophageal or esophagogastric junction tumors who are eligible for elective curative surgery.
✕Probably not a fit
Patients who have already received oncological treatment for their current disease or those unable to consent or cooperate may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to analyze patients with new-onset esophageal and esophagogastric junction tumors in Hungary to identify key prognostic parameters that may influence disease outcomes. Patients will undergo comprehensive assessments including physical, nutritional, and cardiovascular evaluations, along with non-invasive imaging techniques. The study will track changes in various health metrics over time and explore the relationship between these factors and patient morbidity and mortality. The goal is to uncover modifiable factors that could improve treatment outcomes.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic assessments and tailored interventions for patients with esophageal cancer.
How similar studies have gone: While similar studies have explored prognostic factors in cancer, this specific approach focusing on cardiovascular and nutritional parameters in esophageal cancer is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age over 18 years * Diagnosis of new-onset esophageal, esophagogastric junction tumor * Elective curative surgery (open/laparoscopic regardless of surgical technique) * Patients who have not yet received oncological treatment for their present disease Exclusion Criteria: * Lack of consent * Lack of cooperation * Contraindications for some studies: If MR scan is contraindicated, cardiac MR scan is not performed
Where it's running
-
Semmelweis University
Budapest, Hungary Recruiting
Study contacts
- Study coordinator: Tamas Vass
- Email: vass.tamas@semmelweis.hu
- Phone: +36208259039
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Perioperative adebrelimab plus chemotherapy for resectable locally advanced esophageal squamous carcinoma
We will test if giving adebrelimab with preoperative nab‑paclitaxel and cisplatin, followed by postoperative adebrelimab, helps people with resectable locally advanced esophageal squamous carcinoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.